Cargando…

Tocilizumab as a promising agent against COVID-19: Issues and challenges

Detalles Bibliográficos
Autores principales:	Dastan, Farzaneh, Tabarsi, Payam, Abedini, Atefeh, Saffaei, Ali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548894/ https://www.ncbi.nlm.nih.gov/pubmed/34759997 http://dx.doi.org/10.4103/jrms.JRMS_524_20

Ejemplares similares

Tocilizumab administration in a refractory case of COVID-19
por: Dastan, Farzaneh, et al.
Publicado: (2020)

Late Post-Coronavirus Disease 2019 Inflammatory Syndrome: A Case Experience with Tocilizumab
por: Tabarsi, Payam, et al.
Publicado: (2021)

Thalidomide against Coronavirus Disease 2019 (COVID-19): A Medicine with a Thousand Faces
por: Dastan, Farzaneh, et al.
Publicado: (2020)

Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial
por: Dastan, Farzaneh, et al.
Publicado: (2020)

Promising Novel Treatment against Keloids: Antivascular Endothelial Growth Factor Agents
por: Abtahi-Naeini, Bahareh, et al.
Publicado: (2019)

Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial
por: Dastan, Farzaneh, et al.
Publicado: (2020)

A Fourteen-day Experience with Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS): An Iranian Treatment Protocol
por: Jamaati, Hamidreza, et al.
Publicado: (2020)

Continues renal replacement therapy (CRRT) with disposable hemoperfusion cartridge: A promising option for severe COVID-19
por: Dastan, Farzaneh, et al.
Publicado: (2020)

The effects of combination-therapy of tocilizumab and baricitinib on the management of severe COVID-19 cases: a randomized open-label clinical trial
por: Dastan, Farzaneh, et al.
Publicado: (2023)

Combined Therapy of Ciclosporin Plus Favipiravir in the Management of Patients with Severe COVID-19, not Responding to Dexamethasone: A non-Controlled Prospective Trial
por: Barati, Saghar, et al.
Publicado: (2021)

Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial
por: Malekzadeh, Reza, et al.
Publicado: (2020)

Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial
por: Tabarsi, Payam, et al.
Publicado: (2021)

Immunopathogenesis of Pneumonia in COVID-19
por: Alipoor, Shamila D., et al.
Publicado: (2020)

Tocilizumab in severe COVID-19
por: Lucio Liberato, Nicola, et al.
Publicado: (2020)

Favipiravir Effects on the Control of Clinical Symptoms of Hospitalized COVID-19 Cases: An Experience with Iranian Formulated Dosage Form
por: Tabarsi, Payam, et al.
Publicado: (2021)

Oxygenation Efforts for Iranian COVID-19 ARDS Patients: First 5-Day Crisis Experience Scenario
por: Hashemian, Seyed Mohammadreza, et al.
Publicado: (2020)

Efficacy of intravenous immunoglobulins (IVIG) in COVID-19 patients: a systematic review and meta-analysis
por: Fatemi, Behzad, et al.
Publicado: (2023)

Tocilizumab, Adipokines and Severe Complications of COVID-19
por: Fioravanti, Antonella, et al.
Publicado: (2020)

Study Protocol on Antimicrobial Stewardship in a Tertiary Respiratory Referral Hospital
por: Jamaati, Hamidreza, et al.
Publicado: (2018)

Investigation of sarcoidosis patients during COVID-19 pandemic
por: Kiani, Arda, et al.
Publicado: (2020)

Efficacy of Early Prone Positioning Combined with Noninvasive Ventilation in COVID-19
por: Hashemian, Seyed Mohammadreza, et al.
Publicado: (2021)

Could anakinra outmatch dexamethasone/tocilizumab in COVID-19?
por: Gupta, Rahul
Publicado: (2022)

No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial
por: Jamaati, Hamidreza, et al.
Publicado: (2021)

Authors’ Reply to: Tocilizumab, Adipokines and Severe Complications of COVID-19
por: Liu, Bin, et al.
Publicado: (2020)

Silymarin as a Promising Potential Therapeutic Agent for Treatment of Patients with Paraquat Poisoning: An Issue that Merits Further Research
por: Zakariaei, Zakaria
Publicado: (2019)

IgM-enriched immunoglobulin in COVID-19: Case series of 15 severely ill SARS-CoV-2-infected patients
por: Tabarsi, Payam, et al.
Publicado: (2021)

Study of the Effects of Melatonin on Sleep Disorders in Pulmonary Sarcoidosis Patients
por: Feizabadi, Faezeh, et al.
Publicado: (2023)

Effective treatment of severe acute pancreatitis and COVID-19 pneumonia with tocilizumab
por: Zielecki, Piotr, et al.
Publicado: (2020)

High levels of TNFα in patients with COVID-19 refractory to tocilizumab
por: Danlos, F.X., et al.
Publicado: (2021)

High-flow nasal oxygen in severe COVID-19 pneumonia and tocilizumab
por: Mandal, M., et al.
Publicado: (2022)

Anakinra or tocilizumab for prevention of COVID-19 death? A big dilemma
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Scalp necrotic wound and hyperinflammatory shock related to COVID‐19: Topical sucralfate as a promising topical agent
por: Pourmoghaddas, Zahra, et al.
Publicado: (2022)

Correlation between Personality Characteristics and Emotional Intelligence in Iranian Patients with Sarcoidosis
por: Safa, Mitra, et al.
Publicado: (2020)

Combination therapy of IFNβ1 with lopinavir–ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients
por: Baghaei, Parvaneh, et al.
Publicado: (2021)

Vitamin D Usage Among Iranian Population: A Toxicity Crisis is on the Way
por: Esmaily, Hadi, et al.
Publicado: (2019)

Interleukin 6 levels after tocilizumab administration in transplant recipients with COVID-19
por: Gade, Akhil R., et al.
Publicado: (2020)

Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19
por: Foo, Hong, et al.
Publicado: (2023)

Simultaneous Determination of Isoniazid, Pyrazinamide and Rifampin in Human Plasma by High-performance Liquid Chromatography and UV Detection
por: Dasht Bozorg, Behnam, et al.
Publicado: (2019)

Interleukin-6 blockade with tocilizumab in COVID-19: Does it live up to its hype?
por: Kow, C.S., et al.
Publicado: (2021)

Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Authors’ reply
por: Cortegiani, A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_djf3qsu3crbaje7dpkfvnhe7eo